Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2007
03/28/2007EP1765755A1 Regulators of bacterial signalling pathways
03/28/2007EP1765462A1 Topical compositions containing 5'-adenosine-diphosphate ribose
03/28/2007EP1765461A1 Pyk2 inhibitors for stimulation of osteoblast function
03/28/2007EP1765452A1 Delivery system
03/28/2007EP1765430A1 Drug-delivery stent formulations for restenosis and vulnerable plaque
03/28/2007EP1765420A1 Sanitizing composition
03/28/2007EP1765417A2 Immunostimulatory oligonucleotide multimers
03/28/2007EP1765405A1 Combinations comprising antimuscarinic agents and corticosteroids
03/28/2007EP1765404A1 Combinations comprising antimuscarinic agents and beta-adrenergic agonists
03/28/2007EP1765379A2 Pharmaceutical co-crystal compositions and related methods of use
03/28/2007EP1765376A1 Topical compositions and methods for epithelial-related conditions
03/28/2007EP1765373A2 Ozonidzed pharmaceutical composition and method
03/28/2007EP1765372A1 Flavonol-based medicine for treating and/or preventing endoprosthetic restenosis and atheromatous disease in coronary patients
03/28/2007EP1765370A1 Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
03/28/2007EP1765367A1 Phospholipid compositions and methods for their preparation and use
03/28/2007EP1765366A2 Sulphated depolymerised derivates of exopolysaccharides (eps), preparation and uses thereof
03/28/2007EP1765365A2 Compositions and methods ofr the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide
03/28/2007EP1765364A1 Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
03/28/2007EP1765363A2 New compositions
03/28/2007EP1765362A2 Compositions and methods for treatment of neovascular diseases
03/28/2007EP1765361A2 Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle
03/28/2007EP1765360A2 Anti-viral uses of borinic acid complexes
03/28/2007EP1765359A2 Antibiotics containing borinic acid complexes and methods of use
03/28/2007EP1765358A2 Treatment or prevention of skin conditions or tissue conditions in animals using boryloxypyridylmethanones
03/28/2007EP1765357A2 Use of atp analogues for treatment of cardiovascular diseases
03/28/2007EP1765356A1 Spray composition comprising a combination of calcitriol and clobetasol propionate, an alcoholic phase, at least one volatile silicone and one non volatile oily phase
03/28/2007EP1765355A1 Benzoxazine for treating respiratory tract diseases
03/28/2007EP1765354A1 Leptomycin compounds
03/28/2007EP1765353A1 Solid orally ingestible formulations of tetrodotoxin
03/28/2007EP1765352A2 Antagonizing an adenosine a2a receptor to amelioriate one or more components of addictive behavior
03/28/2007EP1765351A1 Protein kinase inhibitors
03/28/2007EP1765350A1 Manufacturing method of solid dispersion containing itraconazole
03/28/2007EP1765349A1 Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
03/28/2007EP1765348A2 Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
03/28/2007EP1765347A2 Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
03/28/2007EP1765346A2 Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
03/28/2007EP1765345A2 A pharmaceutical composition having prokinetic effect and comprising o-(3-piperidino-2-hydroxypropyl)nicotinic amidoxime
03/28/2007EP1765344A2 Cancer treatment method
03/28/2007EP1765343A1 Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting
03/28/2007EP1765342A1 Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for the preparation thereof
03/28/2007EP1765341A2 Methods of treating cellular proliferative disease using naphthalimide and parp-1 inhibitors
03/28/2007EP1765340A1 Sustained release composition for oral administration of niacin
03/28/2007EP1765339A2 Muscarinic acetylcholine receptor antagonists
03/28/2007EP1765338A1 Methods for inducing anti-anxiety and calming effects in animals and humans
03/28/2007EP1765337A1 Combination of anti-hiv reverse transcriptase and protease inhibitors
03/28/2007EP1765336A2 Angiogenesis inhibitors
03/28/2007EP1765335A2 Pyrazole amide derivatives, compositions containing such compounds and methods of use
03/28/2007EP1765334A2 Prodrugs of mitotic kinesin inhibitors
03/28/2007EP1765333A1 Method for inhibiting tumor metastasis
03/28/2007EP1765332A2 Trisubstituted nitrogen modulators of tyrosine phosphatases
03/28/2007EP1765331A1 Methods and compositions for the treatment of pulmonary diseases
03/28/2007EP1765330A2 Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
03/28/2007EP1765329A2 Indoles having anti-diabetic activity
03/28/2007EP1765328A1 Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
03/28/2007EP1765327A2 Compounds, compositions and methods
03/28/2007EP1765326A1 Carbapenem antibacterials with gram-negative activity and processes for their preparation
03/28/2007EP1765325A2 2-substituted heteroaryl compounds
03/28/2007EP1765324A2 Compositions of stable bioactive metabolites of docosahexaenoic (dha) and eicosapentaenoic (epa) acids
03/28/2007EP1765323A1 Use of furan alkyl for preparing an antidiabetic drug
03/28/2007EP1765322A2 Retinal derivatives and methods for the use thereof for the treatment of visual disorders
03/28/2007EP1765321A1 Antimicrobial compositions and methods of use thereof
03/28/2007EP1765320A2 Use of ppar agonists to treat ruminants
03/28/2007EP1765319A1 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
03/28/2007EP1765318A2 Medium chain fatty acids applicable as anti-microbial agents
03/28/2007EP1765317A1 Materials and methods for improving shellfish health, immunity and growth
03/28/2007EP1765316A2 Methods and compositions for modulating bax-ku70-mediated apoptosis
03/28/2007EP1765315A2 Abnormal cannabidiols for lowering intraocular pressure
03/28/2007EP1765314A1 Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
03/28/2007EP1765313A2 Compounds for immunopotentiation
03/28/2007EP1765312A2 Treatment of diseases associated with the use of antibiotics
03/28/2007EP1765311A2 Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
03/28/2007EP1765309A1 Smokeless toabacco product
03/28/2007EP1765308A2 Anti-microbial dental formulations for the prevention and treatment of oral mucosal disease
03/28/2007EP1765305A1 Controlled phase composition technology as an improved process for protection of drugs
03/28/2007EP1765303A1 Oral dosage form safeguarded against abuse
03/28/2007EP1765300A2 Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
03/28/2007EP1765299A1 Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
03/28/2007EP1765298A1 Method for producing a solid dosage form, which is safeguarded against abuse, while using a planetary gear extruder
03/28/2007EP1765296A2 High ibuprofen content granules and their preparation and use
03/28/2007EP1765293A2 Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
03/28/2007EP1765290A2 Stabilised supersaturated solid solutions of steroidal drugs
03/28/2007EP1765288A1 Methods of treatment of endobronchial infections
03/28/2007EP1765287A2 Immediate release formulations of memantine oral dosage forms
03/28/2007EP1765284A1 Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
03/28/2007EP1765283A2 Pharmaceutical compositions
03/28/2007EP1765272A1 Method of decreasing sebum production and pore size
03/28/2007EP1765219A1 Medical devices composed of porous metallic materials for delivering biolgically active materials
03/28/2007EP1765075A1 Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
03/28/2007EP1696958B1 Agents for treatment of glaucomatous retinopathy and optic neuropathy
03/28/2007EP1545552B1 Combination therapy wherein a serotonin reuptake inhibitor is used
03/28/2007EP1513555B1 Formulations of quinapril and related ace inhibitors
03/28/2007EP1499312B1 The use of hydroxypyridone-derivatives in wound healing
03/28/2007EP1497294B1 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS
03/28/2007EP1474441B1 Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c)
03/28/2007EP1453836B1 BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS
03/28/2007EP1443931B1 Ocular iontophoretic device for delivering methotrexate based medicaments and use thereof to treat neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities
03/28/2007EP1414470B1 Micronutrient phosphates as dietary and health supplements
03/28/2007EP1353917B1 Novel process for the synthesis of 5-(4-fluorophenyl)-1-(2-((2r, 4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)-ethyl)-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
03/28/2007EP1335733B1 Treatment of osteoporosis
03/28/2007EP1331933B1 Tiagabine for the treatment of diabetic neuropathy
1 ... 3822 3823 3824 3825 3826 3827 3828 3829 3830 3831 3832 3833 3834 3835 3836 3837 3838 3839 3840 3841 3842 ... 7860